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1. Introduction 
Hypertension is a major risk factor in the development of cardiovascular disease, with 
myocardial infarction, stroke and renal failure being one of the most important health 
problems worldwide due to its high prevalence and deleterious impact on the population in 
terms of excessive morbidity and mortality. Currently, hypertension is estimated to affect 
approximately 30% of the US and European population and 1 thousand million people 
worldwide and, as the population ages, this number is expected to increase even further 
(Wolf-Maier et al., 2003; Kearney et al., 2005; Yoon et al., 2010). Moreover, despite advances 
in treatment of the condition, hypertension control rates continue to be suboptimal in both 
the US and Europe as only about one third have their blood pressure (BP) reduced to the 
recommended levels by the 7th Joint National Committee (JNC-7) to under 140/90 mm Hg 
for uncomplicated hypertension, and less than 130/80 mmHg for those with diabetes 
mellitus or renal disease (Chobanian et al., 2003). 
Hypertension is a controllable disease and effective pharmacological therapies have been 
available for nearly 50 years. Socio-economic conditions, medication non-adherence, 
inadequate prevention strategies and resistant hypertension have all been implicated as 
barriers to adequate BP control. The major pharmacological strategies currently used for 
hypertension management include volume control with diuretics, suppression of central 
and peripheral sympathetic nervous system activity with beta-blockers and alfa-blockers, 
vasodilation with ion channel manipulation and blockade of renin-angiotensin-aldosterone 
system (RAAS). Since monotherapy controls the BP of less than 50% of treated hypertensive 
patients (Materson et al., 1993; Cushman et al., 2002), combination therapy with two or more 
antihypertensive medications with complementary mechanisms is often required to achieve 
BP control to recommended levels (Chobanian et al., 2003; Mancia et al., 2007). At present, 
the most widely used antihypertensive combinations involve hydrochlorothiazide (HCTZ) 
and drugs that block the RAAS, such as angiotensin-converting enzyme (ACE) inhibitors 
and angiotensin II type-1 receptor blockers (ARBs). 
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Recently a new blocker of the RAAS, aliskiren, has been developed and approved by the US 
Food and Drug Administration (FDA, on 5th March 2007) and by the European Medicines 
Agency (EMEA, on 22nd August 2007) for the treatment of essential hypertension. Aliskiren 
is an oral direct renin inhibitor, the rate-limiting enzyme in the production of the end 
product of the RAAS cascade, angiotensin II (Ang II), a potent vasoactive peptide. Aliskiren 
is a long-acting antihypertensive (half-life ≈ 40 hours) and has been shown in several clinical 
trials to be effective in lowering BP, safe and well tolerated in daily doses of 150 and 300 mg 
(approved once-daily doses) (Musini et al., 2009). In a recent systematic review and meta-
analysis of six double-blind randomized clinical trials to quantify the systolic and diastolic 
BP (SBP and DBP) lowering efficacy of aliskiren in the treatment of adults with essential 
hypertension, the obtained weighted mean differences with 95% CI (confidence interval) 
were: aliskiren 150 mg, -5.5 (-6.5, -4.4)/-3.0 (-3.7, -2.3) mm Hg; aliskiren 300 mg, -8.7 (-9.7, -
7.6)/-5.0 (-5.6, -4.3) mm Hg (Musini et al., 2009). 
Several clinical trials revealed that aliskiren/HCTZ combination therapy reduced SBP and 
DBP from baseline to a significantly greater extent than placebo, aliskiren monotherapy and 
HCTZ monotherapy (Chrysant 2008; Baldwin and Plosker 2009). Aliskiren/HCTZ also 
produced significant additional SBP and DBP reductions in patients inadequately 
responsive to 4 weeks’ prior treatment with aliskiren or HCTZ alone (Baldwin and Plosker 
2009). Single-pill combinations (SPCs) of aliskiren/HCTZ (150/12.5 mg, 150/25 mg, 
300/12.5 mg, 300/25 mg) have recently been approved by the US FDA (18th January 2008) 
and by EMEA (16th January 2009) for the treatment of adults with essential hypertension 
whose BP is not adequately controlled with aliskiren or HCTZ alone, and as a substitution 
treatment in patients with hypertension adequately treated by the two individual drugs 
concomitantly at the equivalent fixed dosage. In this chapter, we briefly reviewed the 
pharmacodynamic and pharmacokinetic profile of aliskiren and assessed the 
antihypertensive efficacy and tolerability of the aliskiren/HCTZ combination therapy in 
reducing SBP and DBP in patients with mild to moderate hypertension by using a 
systematic review of the literature and a meta-analytical approach to combine data from 
different clinical trials. 
2. Aliskiren: Pharmacodynamic and pharmacokinetic properties 
A schematic of the RAAS is depicted in Figure 1. Renin is an aspartic protease produced by 
the juxtaglomerular cells in the kidney. This enzyme catalyses the cleavage of 
angiotensinogen, the only know substrate of renin, to the decapeptide angiotensin I (Ang I). 
This is the rate-limiting step of RAAS activation. In the presence of ACE, Ang I is converted 
into the octapeptide hormone Ang II, a potent vasoconstrictor that mediates its activity 
through the type-1 angiotensin II (AT1) receptor. Binding of Ang II to AT1 receptor 
increases BP, and promotes aldosterone secretion from adrenal cortex, sodium reabsorption 
in renal proximal tubules, and catecholamine release from pre-synaptic nerve endings and 
adrenal medulla (Kim and Iwao 2000). Pathological activation of RAAS can result in high BP 
with consequent end-organ damage. 
Several drugs can inhibit the RAAS cascade but redundant biochemical pathways limit the 
potential beneficial effects of these drugs. 
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Fig. 1. The renin-angiotensin-aldosterone system (Staessen et al., 2006). Black arrows show 
stimulation and red arrows show inhibition. Dotted lines show alternative pathways mainly 
documented in experimental studies. Βeta-blockers, renin inhibitors, inhibitors of 
angiotensin-converting enzyme (ACE) and angiotensin II type-1 receptor blockers (ARB) 
reduce the activity of the renin-angiotensin system (RAS). Abbreviations: AT-R, angiotensin 
receptor; EP, endopeptidases; EC, endothelial cells. From reference Staessen et al., with 
permission from Elsevier. 
ACE inhibitors block the conversion of Ang I to Ang II but non-ACE pathways of Ang II 
generation such as a chymase and presumably other enzymes pathways present in end 
organs including heart, kidney and blood vessels get activated under conditions of ACE 
inhibition (Urata et al., 1996; Hollenberg et al., 1998). The existence of alternative pathways 
for Ang II generation that are unaffected by ACE inhibitors raises questions about whether 
ACE is the optimal target for RAAS suppression. Furthermore, ACE inhibitors are not 
specific for RAAS and can prevent ACE-induced inactivation of bradykinin and substance P 
that are thought to be responsible for ACE-inhibitor related side effects as cough and 
angioedema. ARBs exert their effect by blocking AT1 receptors activation by Ang II. This 
may lead to unbalanced activation of other types of receptors such as type-2 and type-4 Ang 
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II receptors (AT2 and AT4 receptors). Physiological role of these receptors are not clear but 
may be important for endothelial function (Wantanabe et al 2005). Over stimulation of AT2 
receptors can generate deleterious agents such as oxygen free radicals, pro-inflammatory 
cytokines and pro-fibrotic mediators and may promote left ventricular hypertrophy 
(Williams 2001; Azizi et al 2006). On the other hand, beneficial effects such as inhibition of 
renin synthesis and Ang II formation are also reported following AT2 receptor activation 
(Siragy et al 2005). Both ACE inhibitors and ARBs stimulate renal renin production by 
interrupting the normal feedback suppression of renin secretion from the kidneys. The 
reactive rise in circulating active renin leads to greater generation of Ang II via pathways 
dependent or independent of ACE. 
2.1 Pharmacodynamic properties of aliskiren 
Recently, a new blocker of RAAS, aliskiren, has been developed and approved for the 
treatment of hypertension. Aliskiren is a direct inhibitor of renin, the enzyme that catalyses 
the conversion of angiotensinogen to Ang I. This is the rate limiting step in the production 
of the end product of RAAS cascade, which makes renin inhibition an attractive option for 
effective RAAS blockade. Renin is measured as plasma renin concentration (PRC) and 
plasma renin activity (PRA). PRC measures the actual amount of renin in plasma regardless 
of its enzymatic activity and is expressed as either μU/mL or pg/mL. PRA denotes the 
enzymatic activity of renin and is measured as the rate of Ang I production after adding 
serum to angiotensinogen and is expressed as ng/ml/hour. Like ACE inhibitors and ARBs, 
aliskiren can reactively lead to an increase in PRC. However, unlike these other inhibitors of 
the RAAS, the effects of renin are suppressed with aliskiren, resulting in a reduction in PRA. 
Aliskiren is a small molecular weight, orally active, non-peptide direct renin inhibitor with 
very high affinity and specificity for human and primate renin (Wood et al., 2003). It is  
significantly less active against renin from dogs, rats, rabbits, pigs and cats, which made the 
process of conducting preclinical experimental studies a challenging one (Wood et al., 2003). 
As a result, these preclinical studies have been performed in marmosets (primates) and 
double-transgenic rats that express the human renin and human angiotensinogen genes 
(Pilz et al., 2005; Wood et al., 2005). 
Aliskiren is a potent inhibitor of renin with an IC50 (concentration inhibiting 50% of activity) 
of 0.6 nmol/L. Aliskiren oral doses of 3 and 10 mg/kg completely suppressed PRA for 24 
hours in mildly sodium depleted marmosets (Wood et al., 2005; Vaidyanathan et al., 2006; 
O'Brien et al., 2007; Vaidyanathan et al., 2007a; Vaidyanathan et al., 2007b). It decreased 
PRA, Ang I and Ang II levels in normotensive volunteers in a dose dependent manner but 
caused a 10-fold increase in PRC (Nussberger et al., 2002). A decrease in plasma and urine 
aldosterone levels were also noted with daily aliskiren doses of 80 mg and above 
(Nussberger et al., 2002). 
Effects of various medications on RAAS pathway are shown in Table 1. With the exception 
of beta-blockers, all other agents blocking RAAS and diuretics including HCTZ increase 
PRC. Aliskiren and ACE inhibitors achieve this by decreasing Ang II levels and ARBs by 
blocking inhibitory effects of Ang II on AT1 receptors on juxtaglomerular cells. Diuretics 
increase PRC by inducing volume depletion. The extent of PRC elevation is more marked 
when aliskiren is combined with HCTZ. PRA is increased by ACE inhibitors, ARBs and 
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HCTZ while aliskiren use alone and in combination with HCTZ is associated with a 
decrease in PRA. Other agents that can decrease PRA include beta-blockers and central alfa-
2 receptor agonists. 
Antihypertensive 
medications 
Enzymes Substrates End-products 
PRC PRA Angiotensinogen Ang I Ang II Ang1-7 Aldosterone 
Beta-blockers ↓ ↓ − ↓ ↓ ↓ ↓ 
ACE inhibitors ↑ ↑ ↓ ↑ ↓ ↑ ↓ 
ARBs ↑ ↑ ↓ ↑ ↑ ↑ ↓ 
Aliskiren ↑↑ ↓↓ - ↓ ↓ ↓ ↓ 
HCTZ ↑ ↑ ↓ ↑ ↑ ↑ ↑ 
Aliskiren/HCTZ 
combination 
↑↑↑ ↓ − − − − − 
Abbreviations: ACE, angiotensin-converting enzyme; Ang I, angiotensin I; Ang II, angiotensin II; Ang 
1–7, angiotensin 1–7; ARBs, angiotensin II type-1 receptor blockers; HCTZ, hydrochlorothiazide; PRA, 
plasma renin activity; PRC, plasma renin concentration; ↑, increased; ↓, decreased; −, unchanged or 
unknown. Adapted from (Sureshkumar 2008). 
Table 1. Antihypertensive medication effects on RAAS pathway 
2.2 Pharmacokinetic properties of aliskiren 
The pharmacokinetic properties of aliskiren have been studied in animals, healthy human 
subjects, patients with compromised liver and kidney function, and subjects with mild 
hypertension (Waldmeier et al., 2007). Aliskiren has a poor bioavailability (2-6%), but this is 
compensated by its high solubility and the already mentioned high inhibitory effect (IC50 = 
0.6 nM) from in vitro inhibition of human renin (Wood et al., 2005; Azizi et al., 2006). 
After oral administration, peak plasma concentrations (Cmax) of aliskiren are reached 
within 1–3 hours (Vaidyanathan et al., 2006; Zhao et al., 2006). When taken with a high-fat 
meal, the mean area under the plasma concentration–time curve (AUC) and Cmax of 
aliskiren are decreased by 71% and 85%, respectively (Novartis_Europharm_Limited 2007. 
Available at http://www.ema.europa.eu/docs/pt_PT/document_library/EPAR_-
_Product_Information/human/000780/WC500047010.pdf. Accessed on 27th August 2011). 
Steady state is achieved after approximately 7 days with once daily dosing (Nussberger et 
al., 2002). Aliskiren is not extensively bound (49.5%) to plasma proteins (Novartis 
Europharm Limited, 2007). The volume of distribution at steady state is 135 L (Novartis 
Europharm Limited, 2007). 
Aliskiren undergoes minimal hepatic metabolism. In vitro studies indicate that aliskiren is a 
substrate of the cytochrome P450 (CYP) 3A4 isoenzyme; however, it is neither an inhibitor 
nor an inducer of CYP isoenzymes (Vaidyanathan et al., 2006). Aliskiren is primarily 
eliminated by the hepatobiliary route as unmetabolized drug. Less than 1% of an orally 
administered dose is excreted in the urine as unchanged drug (Waldmeier et al., 2007). After 
oral administration of a single 300-mg dose of aliskiren to healthy volunteers, the mean ± SD 
clearance corrected for bioavailability [i.e., clearance/drug bioavailability (Cl/F)] was 234 ± 
137 L/hour (Zhao et al., 2006). The terminal half-life of aliskiren ranges from 24–40 hours 
(Nussberger et al., 2002; Azizi et al., 2004; Zhao et al., 2006). This half-life, which is longer 
than the 24-hour dosing interval, is consistent with the observation that plasma 
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concentrations of aliskiren have been shown to accumulate by about 2-fold at steady state 
compared with administration of a single dose (Vaidyanathan et al., 2006). 
3. Aim of the review 
The aim of this review was to assess the antihypertensive efficacy and tolerability of the 
aliskiren/HCTZ combination therapy (as a combination of the individual components or as 
SPCs) in reducing SBP and DBP in patients with mild to moderate hypertension by using 
systematic analysis of the literature and meta-analytical approach to combine data from 
different randomized, double-blind, clinical trials. 
4. Methodology for selection of clinical trials and data analysis 
A literature search to identify clinical trials using aliskiren in combination with HCTZ for 
the treatment of hypertension was conducted on July 2011 to obtain all published study 
reports that met our inclusion criteria. 
4.1 Inclusion and exclusion criteria 
We included all articles in the literature written in any of the major languages. To be 
included in our review studies were required to be randomized, double-blind, clinical trials 
using aliskiren in combination with HCTZ (as a combination of the individual components 
or as SPCs) for the treatment of hypertension. Additionally, studies were included if they 
evaluated the antihypertensive efficacy [outcome measure) of aliskiren/HCTZ in patients 
with mild or moderate essential hypertension (SBP 140-179 mm Hg and/or DBP 90-109 mm 
Hg, as defined in current international guidelines (Mancia et al., 2007)] and patient age ≥ 18 
years. Articles were automatically excluded if their results were not reported or had been 
presented in forms such as abstracts, letters, or commentaries. 
4.2 Literature search strategy 
We searched the following electronic databases: International Pharmaceutical Abstracts, 
MEDLINE, The Cochrane Library and ISI Web of Knowledge. Each database was 
independently searched by 2 reviewers for articles published from 2000 to and including 
June 30, 2011, using the search terms aliskiren, aliskiren/hydrochlorothiazide, aliskiren-
hydrochlorothiazide, aliskiren in combination with hydrochlorothiazide, renin inhibitor. The 
reviewers selected articles based on the predefined inclusion/exclusion criteria and results 
were matched. A consensus method was applied to judge any article selection divergences. 
The rationale for decisions was discussed until reviewers agreed on the final decision. A 
third author was called to resolve any remaining discrepancies concerning article eligibility. 
Selected articles’ references and reviews of the subject were hand searched for additional 
studies that were not obtained through our initial electronic search. 
4.3 Data extraction 
The following information was gathered for each clinical trial: author names, year of 
publication, study design and duration, setting, characteristics of the patients enrolled, sizes 
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of the treatment groups, daily treatment regimens and primary endpoint. Outcomes 
extracted from articles included mean and variation of SBP and DBP at baseline and final 
assessments for each group, responder rate (DBP < 90 mm Hg or ≥10 mm Hg reduction 
from baseline) and BP control rate (SBP < 140 mm Hg and DBP < 90 mm Hg). Changes from 
baseline in PRA and PRC with aliskiren/HCTZ and with either component alone were also 
extracted whenever reported, as well as adverse events recorded during the trials. During 
the data extraction phase, we wrote to corresponding authors of studies to request missing 
data and clarify study details. 
4.4 Quality assessment 
The quality of selected articles was assessed by the same principles used in article selection 
and data extraction (i.e., 2 independent reviewers), and was based on the Jadad et al. 
method to measure the risk of bias (Jadad et al., 1996). Their 3-item quality assessment 
checklist evaluates the following methodological parameters: controlled trial, random 
allocation of treatments, double-blind follow-up, dropout rate, intention-to-treat (ITT) 
analysis and absence of other biases. Quality scores were presented as proportions of the 
total possible score (i.e., 5) of the quality assessment scale (where 100% represents the 
maximum quality). The scores were categorized according to the following criteria: weak 
(<60%), fair (60%), good (80%), or very good (100%). 
4.5 Analysis method 
For trials meeting the criteria for inclusion in the analysis, the efficacy of treatment was 
evaluated via measurements of SBP and DBP at the start of the trial (baseline) and after 8 
weeks of therapy. The meta-analytical approach therefore compared the efficacy of each 
aliskiren/HCTZ dose combination in reducing SBP and DBP over this period of time. The 
analysis method used was based on calculation of the mean BP reduction for a set of 
aliskiren/HCTZ dose combinations evaluated, by weighting the combined data for the trial 
size using the following formula: (BP reduction [trial 1]  number of patients [trial 1] +…+ BP 
reduction [trial n]  number of patients [trial n])/total number of patients (trial 1 +…+ trial n). 
5. Results 
A completed QUOROM flow chart (Moher et al., 1999) of the literature search strategy 
applied and results found is depicted in Figure 2. Initially, 52 potentially relevant RCTs 
were identified that appeared to meet the inclusion criteria and were screened for retrieval 
based on their titles and abstracts. Thirty-six of those articles were excluded for not 
evaluating aliskiren in combination with hydrochlorothiazide. The remaining 16 articles 
were retrieved for full-text review. Eleven of those articles were excluded for the following 
reasons: two had data that were not extractable (Andersen et al., 2008; Andersen et al., 2009), 
three presented excluded study designs (O'Brien et al., 2007; Chrysant et al., 2008; Littlejohn 
et al., 2009), one enrolled patients with severe hypertension (Strasser et al., 2007), four 
appeared only in the abstract form (Sica et al., 2006; Gradman et al., 2007; Prescott et al., 
2007; Calhoun et al., 2008) and one was indexed in MEDLINE in duplicate (Nickenig et al., 
2008). Therefore, after exclusion criteria were applied, a total of 5 studies involving a total of 
5508 patients were included in this analysis [20-24]. 
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Fig. 2. Quorom flow chart of literature search strategy applied and results. Five double-blind 
randomized controlled trials met the inclusion criteria, using aliskiren in combination with 
HCTZ for the treatment of hypertension. 
Table 2 presents the overall characteristics of the evaluated studies. The average sample size 
was 1102 ± 947 (mean ± SD), with a median of 722 and range from 489–2776 patients. All 
included studies were randomized, double-blind, multicenter clinical trials, proceeded by a 
single-blind, placebo (Villamil et al., 2007) / active comparator (Jordan et al., 2007; Nickenig 
et al., 2008; Blumenstein et al., 2009; Geiger et al., 2009), run-in period of 2-4 weeks. 
Moreover, all five studies specified the change from baseline (start of double-blind 
treatment) in mean sitting DBP (msDBP) at 8 weeks as the primary endpoint. 
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Reference 
(Year) 
Study Design, 
Duration, 
Setting, 
BP 
measurement, 
No of patients 
Demographics and 
Baseline 
Characteristicsa 
Daily Treatment Regimens Primary End Point Quality 
Scoreb 
Villamil 
(2007) 
Randomized, 
double-blind, 
placebo-
controlled, 
multicenter; 8 
wks; clinic; 
trough BP; 
n=2776 
Age ≥ 18 yrs. Eligibility 
for single-blind phase: 
msDBP ≥95 and <110 
mmHg (baseline). 
Eligibility for double-
blind phase: msDBP 
≥95 and <110 mmHg 
after 2 or 4 wks on 
placebo. Mean age 55 
yrs; 55% men; 86% 
Caucasian. 
Single-blind, placebo run-in 
period (2 wks or 4 wks): 
Placebo. 
Double-blind treatment (8 
wks): Placebo; 
Aliskiren 75, 150, 300mg; 
HCTZ 6.25, 12.5, 25mg; 
Aliskiren/HCTZ 75/6.25, 
75/12.5, 75/25, 150/6.25, 
150/12.5, 150/25, 300/12.5, 
300/25mg. 
Change in msDBP 
from baseline (start 
of double-blind 
treatment) to wk 8 
endpoint (aliskiren 
monotherapy vs 
placebo; 
combination therapy 
vs respective 
monotherapies) 
60%c 
Jordan 
(2007) 
Randomized, 
double-blind, 
multicenter; 
12 wks; clinic; 
trough BP; 
n=489 
Age ≥ 18 yrs. Eligibility 
for single-blind phase: 
msDBP ≥95 and <110 
mmHg (baseline). 
Eligibility for double-
blind phase: msDBP 
≥90 and <110 mmHg. 
BMI ≥ 30 kg/m2; Mean 
age 54 yrs; 44% men; 
99.6% Caucasian. 
Single-blind treatment (4 
wks): HCTZ 25mg. 
Double-blind treatment 
(first 4 wks – next 8 wks): 
Placebo–HCTZ 25 – 25mg; 
Aliskiren/HCTZ 150/25 - 
300/25mg; 
Irbesartan/HCTZ 150/25 – 
300/25 mg; 
Amlodipine/HCTZ 5/25 – 
10/25mg. 
Change in msDBP 
from baseline (start 
of double-blind 
treatment) to wk 8 
endpoint 
(aliskiren/HCTZ 
300/25 mg vs 
placebo–HCTZ 25 
mg) 
100% 
Nickenig 
(2008) 
Randomized, 
double-blind, 
multicenter; 8 
wks; clinic; 
trough BP; 
n=880 
Age ≥ 18 yrs. Eligibility 
for single-blind phase: 
msDBP ≥95 and <110 
mmHg or msDBP ≥85 
and <110 mmHg if 
treated for HT within 
the 4 wks prior to 
screening (baseline). 
Eligibility for double-
blind phase: msDBP 
≥90 and <110 mmHg 
after 4 wks of aliskiren 
300 mg monotherapy. 
Mean age 55 yrs;55% 
men;83% Caucasian. 
Single-blind treatment  
(4 wks): Aliskiren 300mg. 
Double-blind treatment  
(8 wks): 
Aliskiren 300mg; 
Aliskiren/HCTZ 300/12.5, 
300/25mg. 
Change in msDBP 
from baseline (start 
of double-blind 
treatment) to wk 8 
endpoint (aliskiren 
monotherapy vs 
combination 
therapy) 
100% 
Blumenst
ein (2009) 
Randomized, 
double-blind, 
multicenter; 8 
wks; clinic; 
trough BP; 
n=722 
Age ≥ 18 yrs. Eligibility 
for single-blind phase: 
patients with HT, who 
were newly diagnosed, 
untreated or treated at 
the time of screening. 
Newly diagnosed pts or 
pts who had not been 
treated for HT in the 4 
wks prior to screening 
had to have msDBP ≥95 
and <110 mmHg at the 
time of the screening. 
Eligibility for double-
blind phase: msDBP 
≥90 and <110 mmHg 
after 4 wks of HCTZ 25 
mg monotherapy. 
Mean age 54 yrs; 59% 
men;91% Caucasian. 
Single-blind treatment (4 
wks): HCTZ 25mg. 
Double-blind treatment (8 
wks): 
HCTZ 25mg; 
Aliskiren/HCTZ 150/25, 
300/25mg. 
Change in msDBP 
from baseline (start 
of double-blind 
treatment) to wk 8 
endpoint (HCTZ 
monotherapy vs 
combination 
therapy) 
100% 
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Reference 
(Year) 
Study Design, 
Duration, 
Setting, 
BP 
measurement, 
No of patients 
Demographics and 
Baseline 
Characteristicsa 
Daily Treatment Regimens Primary End Point Quality 
Scoreb 
Geiger 
(2009) 
Randomized, 
double-blind, 
multicenter; 8 
wks; clinic; 
trough BP; 
n=641 
Age ≥ 18 yrs. Eligibility 
for single-blind phase: 
pts with mild to 
moderate HT taking 
antihypertensive 
agents. 
Eligibility for double-
blind phase: msDBP 
≥95 and <110 mmHg 
after 4 wks of HCTZ 
monotherapy. Mean 
age 53 yrs; 57% men; 
86% Caucasian. 
Single-blind treatment (4 
wks): HCTZ 12.5mg for 1 
wk followed by HCTZ 25mg 
for 3 wks. 
Double-blind treatment (8 
wks): HCTZ 25mg; 
Aliskiren/HCTZ 150/25mg 
for 4 wks followed by 
300/25mg for another 4 
wks; 
Valsartan/HCTZ 160/25mg 
for 4 wks followed by 
320/25mg for another 4 
wks; 
Aliskiren/Valsartan/HCTZ 
150/160/25mg for 4 wks 
followed by 300/320/25mg 
for another 4 wks. 
Change in msDBP 
from baseline (start 
of double-blind 
treatment) to wk 8 
endpoint 
(aliskiren/HCTZ 
and 
valsartan/HCTZ vs 
aliskiren/valsartan/
HCTZ) 
60%d 
aIn each published clinical trial, patient baseline and demographic characteristics were comparable for 
all treatment groups. 
bThe percentage of the total possible score (i.e., 5) of the quality assessment scale applied (100% 
represents the maximum quality). 
cMethod to generate the sequence of randomization and method of double blind were not described; 
additionally, some information on outcome variability was not provided. 
dMethod to generate the sequence of randomization and method of double blind were not described. 
Abbreviations: BP, blood pressure; HCTZ, hydrochlorothiazide; HT, hypertension; msDBP, mean sitting 
diastolic blood pressure; pts, patients; wk, week. 
Table 2. Published clinical trials of aliskiren/HCTZ for treatment of mild to moderate 
hypertension 
Secondary efficacy measures included the change in mean sitting SBP (msSBP) (Jordan et al., 
2007; Villamil et al., 2007; Nickenig et al., 2008; Blumenstein et al., 2009; Geiger et al., 2009), 
the proportion of patients with successful response to treatment (defined as msDBP < 90 
mmHg and/or a ≥ 10 mmHg reduction from baseline) (Jordan et al., 2007; Villamil et al., 
2007) and the proportion of patients attaining BP control (defined as msDBP < 90 mmHg 
and msSBP < 140 mm Hg) (Jordan et al., 2007; Villamil et al., 2007; Nickenig et al., 2008; 
Blumenstein et al., 2009; Geiger et al., 2009). Two trials used the SPC (Jordan et al., 2007; 
Villamil et al., 2007), and three combined the individual components (Nickenig et al., 2008; 
Blumenstein et al., 2009; Geiger et al., 2009), with aliskiren and HCTZ administered orally as 
single daily doses in all studies. One trial enrolled obese hypertensive patients only (obesity 
defined as body mass index of ≥ 30 kg/m2) (Jordan et al., 2007), although in the remaining 
four trials subgroups of patients with obesity were also present. In the five included clinical 
trials patient demographics and baseline characteristics were similar across treatment 
groups. Brief details of the characteristics of each individual trial and treatment group, 
including mean patient ages, sex ratios, body mass index / obesity and baseline SBP and 
DBP are provided in Table 3. 
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Reference Pts., n Treatment and daily dose 
(mg) 
Patient age 
(years) 
Sex ratio 
(M/F) 
BMI 
(kg/m2) 
Obese 
(BMI ≥ 30 
kg/ m2) 
(%) 
SBP 
baseline 
(mm Hg) 
DBP 
baseline 
(mm Hg) 
Villamil 
(2007) 
195 
184 
185 
183 
194 
188 
176 
188 
193 
186 
176 
186 
188 
181 
173 
Placebo 
Aliskiren 75 
Aliskiren 150 
Aliskiren 300 
HCTZ 6.25 
HCTZ 12.5 
HCTZ 25 
Aliskiren/HCTZ 75/6.25 
Aliskiren/HCTZ 75/12.5 
Aliskiren/HCTZ 75/25 
Aliskiren/HCTZ 150/6.25 
Aliskiren/HCTZ 150/12.5 
Aliskiren/HCTZ 150/25 
Aliskiren/HCTZ 300/12.5 
Aliskiren/HCTZ 300/25 
54.4 
55.0 
53.5 
54.2 
55.2 
55.4 
55.1 
55.1 
54.4 
54.7 
53.9 
54.7 
53.7 
55.5 
54.8 
109/86 
103/81 
112/73 
99/84 
109/85 
103/85 
92/84 
108/80 
101/92 
101/85 
96/80 
98/88 
104/84 
89/92 
98/75 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
NR 
40.5 
41.8 
32.4 
38.8 
41.2 
38.8 
32.4 
37.8 
39.9 
38.7 
37.5 
35.5 
37.8 
42.0 
41.0 
152.7 
153.2 
153.4 
154.4 
153.4 
153.4 
154.5 
154.5 
154.0 
152.9 
153.3 
154.1 
153.2 
153.2 
154.6 
99.3 
99.4 
98.8 
99.3 
99.3 
99.1 
99.1 
98.9 
100.0 
99.0 
99.0 
99.1 
98.4 
99.5 
99.3 
Jordan 
(2007) 
122 
122 
119 
126 
HCTZ 25 
Aliskiren/HCTZ 300/25 
Irbesartan/HCTZ 300/25 
Amlodipine/HCTZ 10/25 
55.2±12.3 
53.1±11.9 
53.0±11.0 
55.2±11.9 
52/70 
60/62 
48/71 
53/73 
34.0±4.1 
34.8±5.2 
34.3±4.7 
34.5±4.1 
NR 
NR 
NR 
NR 
149.5±11.3 
149.4±11.6 
149.1±13.4 
149.8±11.5 
97.2±4.6 
96.8±4.9 
96.6±4.4 
96.7±5.0 
Nickenig 
(2008) 
298 
293 
289 
Aliskiren 300 
Aliskiren/HCTZ 300/12.5 
Aliskiren/HCTZ 300/25 
55.5±10.6 
54.9±10.5 
54.4±10.3 
159/139 
155/138 
172/117 
29.2±4.5 
29.2±4.9 
28.9±4.6 
NR 
NR 
NR 
149.8±12.6 
150.3±12.5 
150.8±12.8 
95.5±4.4 
95.5±4.3 
95.8±4.7 
Blumenstein 
(2009) 
246 
244 
232 
HCTZ 25 mg 
Aliskiren/HCTZ 150/25 
Aliskiren/HCTZ 300/25 
52.9±11.5 
53.6±11.1 
54.1±9.5 
143/103 
144/100 
140/92 
29.7±5.0 
28.9±4.7 
29.9±5.0 
NR 
NR 
NR 
151.8±11.9 
151.2±12.7 
151.1±12.3 
96.3±4.9 
96.1±4.9 
96.1±4.6 
Geiger 
(2009) 
152 
166 
155 
168 
HCTZ 25 
Aliskiren/HCTZ 300/25 
Valsartan/HCTZ 320/25 
Aliskiren/Valsartan/HCT
Z 300/320/25 
52.6±9.93 
52.3±10.90 
55.0±11.40 
52.9±10.83 
94/58 
92/74 
88/67 
91/77 
31.8±6.13 
31.3±6.28 
31.3±5.85 
31.9±6.21 
NR 
NR 
NR 
NR 
154.1±12.61 
153.3±12.68 
156.7±12.49 
152.7±11.64 
99.9±4.33 
99.3±4.10 
99.9±3.97 
99.2±3.70 
Values are mean ±SD unless otherwise stated. 
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; F, female; HCTZ, 
hydrochlorothiazide; M, male; NR, not reported; Pts, patients; SBP, systolic blood pressure. 
Table 3. Main patient baseline and demographic characteristics by treatment group of the 
included clinical trials (randomized population) 
The average quality score of study reporting was 84% ± 22% (range 60–100%), which could 
be categorized as very good. One study failed to report all information on data variability 
(Villamil et al., 2007), which prevented the use of an approximation for standard error of the 
mean (SEM) or confidence interval (CI) estimation, when calculating some weighted 
average reductions in SBP and DBP. We contacted the corresponding author of this study by 
email to request missing data on SEM as well as on BP control rate at endpoint for each 
aliskiren/HCTZ, aliskiren and HCTZ daily doses tested, but no response was provided. 
Table 4 details results from clinical trials on the efficacy of aliskiren/HCTZ in reducing BP. 
In the only placebo-controlled study (and also the largest of the RCTs), aliskiren/HCTZ 
combination reduced SBP and DBP from baseline to a significantly (p ≤ 0.0001) greater 
extent than placebo in patients with mild to moderate hypertension (Villamil et al., 2007). 
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Reference Patients, n 
(ITT) 
Treatment and daily dose 
(mg) 
Change in SBP 
from baseline at 
endpoint (mm 
Hg) 
Change in 
DBP from 
baseline at 
endpoint (mm 
Hg) 
Responder 
rate (%) 
BP control rate at 
endpoint (%) 
Villamil 
(2007) 
192 
183 
183 
180 
194 
188 
173 
187 
189 
186 
173 
184 
187 
180 
173 
Placebo 
Aliskiren 75 
Aliskiren 150 
Aliskiren 300 
HCTZ 6.25 
HCTZ 12.5 
HCTZ 25 
Aliskiren/HCTZ 75/6.25 
Aliskiren/HCTZ 75/12.5 
Aliskiren/HCTZ 75/25 
Aliskiren/HCTZ 150/6.25 
Aliskiren/HCTZ 150/12.5 
Aliskiren/HCTZ 150/25 
Aliskiren/HCTZ 300/12.5 
Aliskiren/HCTZ 300/25 
-7.5 
-9.4 
-12.2b 
-15.7c 
-11.0a 
-13.9c 
-14.3c 
-14.3 ±0.93c,d 
-15.6c 
-17.3c,d 
-15.3c 
-17.6c,d 
-19.5c,d 
-19.8c,d 
-21.2±0.97c,d 
-6.9 
-8.7±0.59a 
-8.9±0.59a 
-10.3±0.60c 
-9.1±0.58a 
-10.1±0.59c 
-9.4±0.61a 
-10.8c,d 
-11.1c 
-11.5c,d 
-10.4±0.59c 
-11.9c,d 
-12.7c,d 
-13.9c,d 
-14.3±0.61c,d 
45.8 
51.9 
51.9 
63.9b 
53.6 
60.6a 
59.0a 
61.5a 
63.5b 
70.4c,d 
58.4a 
69.6c 
71.1c,d 
80.6c,d 
76.9c,d 
28.1 
(29.0 
to 
c               46.7) 
(32.5 
to 
37.8) 
 
a 
a,d 
a               (37.4 
a,d                to 
a,d              59.5) 
a,d 
a,d 
Jordan 
(2007) 
117 
113 
117 
122 
HCTZ 25 
Aliskiren/HCTZ 300/25 
Irbesartan/HCTZ 300/25 
Amlodipine/HCTZ 10/25 
-8.6±1.00 
-15.8±1.01e 
-15.4±1.00h 
-13.6±0.98h 
-7.9±0.73 
-11.9±0.74e 
-11.3±0.72h 
-10.3±0.71h 
59.0 
73.5f 
70.9h 
68.0h 
34.2 
56.6g 
54.7h 
45.1i 
Nickenig 
(2008) 
296 
292 
284 
Aliskiren 300 
Aliskiren/HCTZ 300/12.5 
Aliskiren/HCTZ 300/25 
-8.0±0.9 
-13.5±0.9j 
-15.9±0.9j 
-7.4±0.5 
-10.5±0.5j 
-11.0±0.6j 
62.2 
73.3k 
77.1j 
40.9 
57.9j 
60.2j 
Blumenstei
n (2009) 
244 
242 
232 
HCTZ 25 mg 
Aliskiren/HCTZ 150/25 
Aliskiren/HCTZ 300/25 
-7.1±0.7 
-12.9±0.7l 
-16.7±0.7l,m 
-4.8±0.4 
-8.5±0.4l 
-10.7±0.4l,n 
47.1 
67.4l 
78.5l 
25.8 
48.8l 
58.2l,o 
Geiger 
(2009) 
151 
164 
154 
168 
HCTZ 25 
Aliskiren/HCTZ 300/25 
Valsartan/HCTZ 320/25 
Aliskiren/Valsartan/HCT
Z 300/320/25 
-6±1.12 
-15 ±1.08l 
-18 ±1.12l 
-22±1.07l,p,q 
-6±0.70 
-11±0.67l 
-14±0.70l 
-16±0.67l,p,q 
NR 
NR 
NR 
NR 
20.53 
40.85l 
48.70l 
66.67l,p,r 
Changes in blood pressure are presented as the least-squares mean changes (with ± SEM, whenever 
provided by the authors). 
aP < 0.05, bP < 0.001, cP ≤ 0.0001 vs placebo; dP < 0.05 vs each component monotherapy; eP < 0.0001 vs 
HCTZ 25 mg; fP < 0.05 vs HCTZ 25 mg; gP = 0.0005 vs HCTZ 25 mg; hP > 0.05 vs aliskiren/HCTZ 
300/25 mg; iP = 0.052 vs aliskiren/HCTZ 300/25 mg; jP < 0.001 vs aliskiren 300 mg; kP = 0.002 vs 
aliskiren 300 mg; lP < 0.001 vs HCTZ 25 mg; mP = 0.009 vs aliskiren/HCTZ 150/25 mg; nP < 0.001 vs 
aliskiren/HCTZ 150/25 mg; oP = 0.033 vs aliskiren/HCTZ 150/25 mg; pP < 0.001 vs aliskiren/HCTZ 
300/25 mg; qP < 0.01 vs valsartan/HCTZ 320/25 mg; rP < 0.001 vs valsartan/HCTZ 320/25 mg. 
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; ITT, 
intention-to-treat analysis; NR, not reported; SBP, systolic blood pressure. 
Table 4. Clinical trial data on the efficacy of aliskiren/HCTZ in reducing blood pressure 
Furthermore, aliskiren/HCTZ combination (at all but the 75/12.5 mg and 150/6.25 mg 
dosages, both of which are not commercially available) decreased SBP and DBP from 
baseline to a significantly (p < 0.05) greater extent than the component monotherapies 
(Villamil et al., 2007). In the other selected RCTs, all of which with an active comparator and 
a non-responder study design (Jordan et al., 2007; Nickenig et al., 2008; Blumenstein et al., 
2009; Geiger et al., 2009), aliskiren/HCTZ combination was an effective treatment option, 
producing significantly additional reductions in SBP and DBP in patients with mild to 
moderate hypertension inadequately responsive to 4 weeks’ prior treatment with aliskiren 
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(Nickenig et al., 2008) or HCTZ (Jordan et al., 2007; Blumenstein et al., 2009; Geiger et al., 
2009) alone. In the five included RCTs, BP control rates were also significantly higher with 
all aliskiren/HCTZ combinations commercially available than with placebo, aliskiren alone 
and HCTZ alone. One of the included studies did not report the BP response rate (Geiger et 
al., 2009), in the remaining four studies, BP response rates were also significantly higher 
with all aliskiren/HCTZ combinations commercially available than with placebo; however, 
only the three higher dosages of aliskiren/HCTZ combinations yielded significantly higher 
BP response rates than the component monotherapies (Jordan et al., 2007; Villamil et al., 
2007; Nickenig et al., 2008; Blumenstein et al., 2009). 
Two studies also compared the efficacy of aliskiren/HCTZ 300/25 mg combination in 
reducing and controlling BP with other treatment combinations (amlodipine/HCTZ 10/25 
mg, irbesartan/HCTZ 300/25 mg, valsartan/HCTZ 320/25 mg and 
aliskiren/valsartan/HCTZ 300/320/25 mg) (Jordan et al., 2007; Geiger et al., 2009). Only the 
last combination yielded significantly greater decreases in SBP and DBP and higher BP 
control rates than the aliskiren/HCTZ 300/25 mg combination (Geiger et al., 2009). 
Aliskiren/HCTZ 
combination 
evaluated 
Number 
of clinical 
trials 
Total 
number of 
patients 
Change in SBP 
from baseline at 
endpoint (mm Hg) 
Change in DBP 
from baseline at 
endpoint (mm Hg) 
BP control 
rate (%)a 
Aliskiren/HCTZ 
150/12.5 mg 
1 184 -17.6 -11.9 [37.4, 59.5]a 
Aliskiren/HCTZ 
150/25 mg 
2 429 -15.8 -10.3 [43.8, 53.5]a 
Aliskiren/HCTZ 
300/12.5 mg 
2 472 -15.9 -11.8 [50.1, 58.5]a 
Aliskiren/HCTZ 
300/25 mg 
5 966 -16.9±0.4 -11.6±0.3 [51.9, 55.9]a 
Changes in blood pressure are presented as the weighted least-squares mean changes ± SEM (not all 
variability information was provided in the trial of Villamil (2007), preventing the use of an 
approximation for SEM or confidence intervals estimation for the first three aliskiren/HCTZ dose 
combinations). 
aThe range presented is due to the trial of Villamil (2007), which presented the range of BP control rate 
for aliskiren/HCTZ combination, without specify the values for each dose combination. 
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; SBP, 
systolic blood pressure. 
Table 5. Weighted average reductions from baseline of SBP and DBP and BP control rate for 
each aliskiren/HCTZ combination commercially available 
The Q statistic for heterogeneity of effects was not significant, both for SBP (χ2 = 1.14, p = 
0.89) and for DBP (χ2 = 0.62, p = 0.96); therefore we considered the study results to be 
combinable and a fixed-effects model was used in the analysis. Table 5 presents the 
weighted mean reductions from baseline of SBP and DBP and BP control rate for each 
aliskiren/HCTZ combination commercially available. It should be noted that four RCTs 
were not placebo-controlled and, furthermore, the active comparator (aliskiren or HCTZ) 
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differed in these studies (Jordan et al., 2007; Nickenig et al., 2008; Blumenstein et al., 2009; 
Geiger et al., 2009). In these circumstances, appraisal of the change from baseline in SBP and 
DBP achieved by each aliskiren/HCTZ combination allows some appreciation of their 
antihypertensive efficacy since all data are derived from studies of similar design. 
Nevertheless, the higher BP reductions reported in the Villamil (2007) trial (Villamil et al., 
2007) with aliskiren/HCTZ (a fact also observed with aliskiren and HCTZ monotherapies) 
must be observed with some caution, as they clearly diverged upward from the results 
obtained by other authors and yielded an unexpected higher effect of the lowest dose of 
aliskiren/HCTZ commercially available (150/12.5 mg). 
 
Reference 
Pts., n 
(ITT) 
Treatment and daily dose 
(mg) 
Δ in PRA 
from 
pretreatm
enta or 
baselineb, c 
(%) 
Δ in PRC from 
pretreatmenta 
or baselineb,c 
(%) 
Adverse Events 
Villamil 
(2007) 
192 
183 
183 
180 
194 
188 
173 
187 
189 
186 
173 
184 
187 
180 
173 
Placebo 
Aliskiren 75 
Aliskiren 150 
Aliskiren 300 
HCTZ 6.25 
HCTZ 12.5 
HCTZ 25 
Aliskiren/HCTZ 75/6.25 
Aliskiren/HCTZ 75/12.5 
Aliskiren/HCTZ 75/25 
Aliskiren/HCTZ 150/6.25 
Aliskiren/HCTZ 150/12.5 
Aliskiren/HCTZ 150/25 
Aliskiren/HCTZ 300/12.5 
Aliskiren/HCTZ 300/25 
+0.7d 
-54.2 
-65.1 
-57.6 
+3.5 
+44.7 
+71.9 
-54.5 
NR 
NR 
NR 
-49.6 
NR 
NR 
-62.3 
+30 
+164 
+192 
+348 
+10e 
+26e 
+108 
PRC increased 
in all 
combination 
groups and 
was related to 
dosages of 
both drugs. 
+1211 
The overall incidence of treatment-related 
adverse events (AEs) was slightly higher in 
the HCTZ (9.3-11.0%) and combination 
groups (8.7-16.6%) compared with placebo 
(8.8%) and aliskiren (6.5-9.8%) groups. 
However, this could not be attributed to any 
particular AE or class of AE. Hypokalaemia 
(serum potassium <3.5 mmol/L) occurred 
with the highest frequency in HCTZ 12.5 
and 25mg groups (3.9 and 5.2%, 
respectively). When these doses of HCTZ 
were administered in combination with 
aliskiren, the frequency of hypokalaemia 
decreased to 0.7–2.0% for the combination 
groups with HCTZ 12.5mg and to 2.2–3.4% 
for the combination groups with HCTZ 
25mg. 
Jordan 
(2007) 
117 
113 
117 
122 
HCTZ 25 
Aliskiren/HCTZ 300/25 
Irbesartan/HCTZ 300/25 
Amlodipine/HCTZ 10/25 
+46.3f 
-45.0f 
+536.6f 
+195.6f 
NR 
NR 
NR 
NR 
Amlodipine/HCTZ group had the highest 
rate of AEs (45.2%) because of a higher 
incidence of peripheral edema. Incidence of 
AEs in the other treatment groups was: 
39.3% - aliskiren/HCTZ; 38.5% – HCTZ; 
36.1% - Irbesartan/HCTZ. The proportion of 
patients experiencing nasopharyngitis, 
dizziness and hyperkalaemia were slightly 
higher in aliskiren/HCTZ group (8.2%, 3.3% 
and 5.7%, respectively). 
Nickenig 
(2008) 
296 
292 
284 
Aliskiren 300 
Aliskiren/HCTZ 300/12.5 
Aliskiren/HCTZ 300/25 
NR 
NR 
NR 
NR 
NR 
NR 
Aliskiren/HCTZ SPC treatment showed 
similar tolerability to aliskiren monotherapy. 
Headache, hypercholesterolemia and 
nasopharyngitis occurred in ≥2% of patients 
in any treatment group. The proportion of 
patients with hypokalaemia was lower in the 
aliskiren/HCTZ 300/12.5 mg group (0.4%) 
and aliskiren 300 mg monotherapy group 
(0.4%) than in the aliskiren/HCTZ 300/25 
mg group (2.5%). 
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Reference 
Pts., n 
(ITT) 
Treatment and daily dose 
(mg) 
Δ in PRA 
from 
pretreatm
enta or 
baselineb, c 
(%) 
Δ in PRC from 
pretreatmenta 
or baselineb,c 
(%) 
Adverse Events 
Blumenstein 
(2009) 
244 
242 
232 
HCTZ 25 
Aliskiren/HCTZ 150/25 
Aliskiren/HCTZ 300/25 
NR 
NR 
NR 
NR 
NR 
NR 
Aliskiren/HCTZ SPC treatment showed 
similar tolerability to HCTZ alone and a 
numerically lower incidence of 
hypokalaemia (aliskiren/HCTZ, 1.3-2.2%; 
HCTZ alone, 3.4%). AEs reported in ≥2% of 
patients in any treatment group were 
nasopharyngitis, dizziness, back pain and 
vertigo. 
Geiger 
(2009) 
151 
164 
154 
168 
HCTZ 25  
Aliskiren/HCTZ 300/25 
Valsartan/HCTZ 320/25 
Aliskiren/Valsartan/HCT
Z 300/320/25 
-13.2g 
-40.5h 
+509.5h 
+38.9g 
-29.1i 
+489.8j 
+561.4j 
+1760.1j 
Aliskiren/HCTZ SPC treatment showed 
similar tolerability to HCT alone and a 
numerically lower incidence of 
hypokalaemia (aliskiren/HCTZ, 5.0%; 
HCTZ alone, 9.3%), nasopharyngitis 
(aliskiren/HCTZ, 3.0%; HCTZ alone, 6.6%) 
and headache (aliskiren/HCTZ, 2.4%; HCTZ 
alone, 5.3%). 
aJordan (2007); bVillamil (2007); cGeiger (2009); dP > 0.05 vs baseline; eP > 0.05 vs placebo; fP < 0.05 vs 
pretreatment; gP > 0.75 vs baseline; hP < 0.001 vs baseline; iP ≥ 0.05 vs baseline; jP < 0.05 vs baseline. 
Abbreviations: AE, adverse event; HCTZ, hydrochlorothiazide; ITT, intention-to-treat analysis; NR, not 
reported; PRA, plasma renin activity; PRC, plasma renin concentration; Pts, patients; SPC, single-pill 
combination. 
Table 6. Changes from baseline in PRA and PRC with aliskiren and HCTZ monotherapy and 
combination therapy 
Some authors also studied changes from pre-treatment (Jordan et al., 2007) (start of single-
blind treatment) or baseline (Villamil et al., 2007; Geiger et al., 2009) (start of double-blind 
treatment) in PRA and PRC with aliskiren and HCTZ monotherapy and combination 
therapy (Table 6). Aliskiren 75, 150 and 300 mg/day decreased (the geometric) PRA from 
baseline by 54.2%, 65.1% and 57.6%, respectively (Villamil et al., 2007). Conversely, HCTZ 
monotherapy significantly increased PRA at 12.5 and 25 mg/day dosages (Jordan et al., 
2007; Villamil et al., 2007). When combined, aliskiren/HCTZ significantly reduced PRA 
from pretreatment (by 45%) (Jordan et al., 2007) and baseline (by 40.5-62.3%) (Villamil et al., 
2007; Geiger et al., 2009), whereas combined treatment with amlodipine/HCTZ, 
irbesartan/HCTZ and valsartan/HCTZ significantly increased PRA (Jordan et al., 2007; 
Geiger et al., 2009). Aliskiren elevated PRC from baseline in a dose-dependent manner, with 
increases of 164%, 192% and 348% at dosages of 75, 150 and 300 mg/day, respectively 
(Villamil et al., 2007). HCTZ 25 mg/day increased PRC by 108%, whereas lower dosages did 
not cause alterations in PCR that significantly differed from placebo. All aliskiren/HCTZ 
combinations significantly increased PCR (Villamil et al., 2007; Geiger et al., 2009), the 
magnitude of increases was related to the dosages of both components, with the most 
marked increase (1211% from baseline) occurring in the aliskiren/HCTZ 300/25 mg group 
(Villamil et al., 2007). Furthermore, increases in PRC in several combination groups were 
considerably greater than the sum of the increases seen with each component (Villamil et al., 
2007). It should be noted that Geiger et al measured the baseline PRA and PCR at the end of 
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the 4-week single-blind HCTZ period (Geiger et al., 2009). Therefore, the effect of HCTZ on 
PRA and PRC might have been stabilized with this initial therapy and no further changes 
after the 8-week additional HCTZ treatment was observed (Geiger et al., 2009). 
Table 6 also describes the most common adverse events reported in the clinical trials. 
Aliskiren/HCTZ, as a SPC or as a combination of the individual components concurrently 
administered, was generally well tolerated in the five clinical trials reviewed. The majority 
of adverse events were mild and transient in nature, with the most commonly reported 
events including nasopharyngitis (Jordan et al., 2007; Villamil et al., 2007; Nickenig et al., 
2008; Blumenstein et al., 2009; Geiger et al., 2009), headache (Jordan et al., 2007; Villamil et 
al., 2007; Nickenig et al., 2008; Blumenstein et al., 2009; Geiger et al., 2009), dizziness (Jordan 
et al., 2007; Blumenstein et al., 2009), back pain (Blumenstein et al., 2009), vertigo 
(Blumenstein et al., 2009) and hypercholesterolemia (Nickenig et al., 2008). 
The proportion of patients experiencing hypokalaemia (defined as serum potassium levels 
<3.5 mmol/L) were numerically lower with aliskiren/HCTZ than with HCTZ alone 
(Villamil et al., 2007; Blumenstein et al., 2009; Geiger et al., 2009). The proportion of patients 
with hypokalaemia was also lower in the aliskiren/HCTZ 300/12.5 mg group (0.4%) and 
aliskiren 300 mg monotherapy group (0.4%) than in the aliskiren/HCTZ 300/25 mg group 
(2.5%) (Nickenig et al., 2008). In obese hypertensive patients, hypokalaemia occurred in 4.9% 
patients of the aliskiren/HCTZ group versus 2.5%, 10.3% and 4.1% of patients treated with 
irbesartan/HCTZ, amlodipine/HCTZ or HCTZ alone, respectively (Jordan et al., 2007). 
6. Discussion 
SPCs of aliskiren/HCTZ has recently been introduced in European Union for the second-
line treatment of adults with essential hypertension whose BP is not adequately controlled 
with either drug alone, or as a substitution treatment in patients with hypertension 
adequately treated by the two individual drugs concomitantly at the equivalent fixed 
dosage. To our knowledge, this study represents the first published meta-analytical 
approach to the efficacy of aliskiren/HCTZ in reducing BP in patients with mild to 
moderate hypertension. Although other reviews dealing with the same topic are available in 
the literature, no study has provided a synthesis of data from clinical trials. 
The five studies included in this systematic review are short-term (8-12 weeks) randomized, 
double-blind, clinical trials with a similar design and comparable primary endpoints and 
secondary efficacy measures. All studies compared the change in SBP and DBP from baseline 
(start of double-blind treatment) to week 8 endpoint in each aliskiren/HCTZ combination 
group with that in placebo and/or aliskiren monotherapy and/or HCTZ monotherapy group. 
Patient demographics and baseline characteristics were also similar across treatment groups in 
all included studies, except that one study included obese patients only (Jordan et al., 2007). 
The average quality of the articles was considered to be very good. 
In this study we chose to present the results by way of weighted average sums of BP 
reductions over 8 weeks, a period consistent with current clinical recommendations for 
assessing the clinical efficacy and tolerability of antihypertensive drugs following their 
initiation (Chobanian et al., 2003; Mancia et al., 2007). The weighted means method, which 
has been used in other meta-analyses (Conlin et al., 2000; Baguet et al., 2005; Baguet et al., 
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2007), takes into account the different sizes of trials and provides results that are easy to 
interpret clinically. 
In all clinical trials selected for analysis, commercially available aliskiren/HCTZ 
combinations (150/12.5 mg, 150/25 mg, 300/12.5 mg and 300/25 mg) provided clinically 
significant additional SBP and DBP reductions and improved BP control rates over aliskiren 
or HCTZ monotherapy, which demonstrates that aliskiren/HCTZ SPCs are a effective 
treatment option for patients with mild to moderate hypertension who do not achieve BP 
control with aliskiren 300 mg or HCTZ 25 mg alone. A meta-analysis of 354 randomized 
clinical trials involving more than 40,000 treated patients with hypertension revealed that 
the additional reduction in BP achieved with antihypertensive combination therapy versus 
monotherapy provide a reduced risk of stroke and ischemic heart events (Law et al., 2003). 
In another meta-analysis, examining individual data from one million adults in 61 
prospective studies, it was found that, at ages 40-69 years, each increase of 20 mm Hg usual 
SBP (or, approximately equivalently, 10 mm Hg usual DBP) is associated with more than a 
twofold difference in the stroke death rate, and with twofold differences in the death rates 
from ischaemic heart disease and from other vascular causes (Lewington et al., 2002). Thus, 
the additional mean BP reductions of up to 8.0/4.8 mmHg (versus HCTZ 25 mg) or 6.0/3.1 
mmHg (versus aliskiren 300 mg) provided by aliskiren/HCTZ 300/25 mg in the present 
analysis might be expected to reduce the risk of cardiovascular mortality. However, long-
term and large-scale studies analysing the effects of aliskiren/HCTZ combination therapy 
on clinical outcomes are required to confirm this hypothesis. 
The capacity of aliskiren to enhance the antihypertensive efficacy of HCTZ reflects its 
complementary mode of action, targeting the RAAS at its point of activation and thus 
suppressing PRA. HCTZ monotherapy increased PRA, as a result of stimulated renin release 
in response to reduced intravascular volume. The addition of aliskiren counteracted this 
effect, resulting in a significant (p < 0.05) overall decrease in PRA compared with HCTZ 
monotherapy (Jordan et al., 2007; Villamil et al., 2007; Geiger et al., 2009). Furthermore, 
aliskiren effectively inhibited the renin enzyme, despite marked elevation in PRC, to 
produce an overall reduction in PRA from baseline. This contrasts to agents that block the 
RAAS at other points, such as ACE inhibitors and ARBs, which induce increases in PRA in 
parallel with PRC (Nussberger et al., 2002; Jordan et al., 2007; Geiger et al., 2009). 
Aliskiren/HCTZ was generally well tolerated in the clinical trials reviewed and not 
associated with a notably higher incidence of adverse events than treatment with either 
component alone. These results are consistent with a long-term open-label study in 1955 
hypertensive patients showing that aliskiren/HCTZ free combinations were well tolerated 
over up to 12 months of treatment (Sica et al., 2006; Gradman et al., ) 2007). In three included 
trials, when aliskiren and HCTZ was administered in combination, aliskiren opposed the 
adverse hypokalaemic effects of HCTZ (Villamil et al., 2007; Blumenstein et al., 2009; Geiger 
et al., 2009). The safety profile of an aliskiren/valsartan/HCTZ combination was also 
investigated in one clinical trial and was similar to the 2-drug combinations 
(aliskiren/HCTZ or valsartan/HCTZ), with a greater BP-lowering effect in patients not 
adequately responding to HCTZ monotherapy (Geiger et al., 2009). 
Most patients with hypertension will require combination treatment with two or more 
antihypertensive medications in order to achieve BP control to recommended levels 
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(Chobanian et al., 2003; Mancia et al., 2007). A meta-analysis of adherence studies showed 
that the use of SPC regimens reduced the rate of non-compliance by 24–26% compared with 
respective free combinations (Bangalore et al., 2007). Aliskiren/HCTZ SPCs therefore offers 
the convenience of a single-tablet once daily treatment regimen, which may improve 
treatment compliance and subsequent BP control. 
The limitations of this study should be noted. Firstly, the intervention effect size as reported 
above (Tables 2 and 3) could be an overestimate due to publication bias since the manufacturer 
(Novartis Pharmaceuticals Corporation) sponsored four (Jordan et al., 2007; Nickenig et al., 
2008; Blumenstein et al., 2009; Geiger et al., 2009) of the included published studies and one 
author of the remaining study (Villamil et al., 2007) is employee of Novartis Pharmaceuticals 
Corporation. It is possible that less optimistic studies have not been published and therefore 
not included in our analysis. Secondly, because the BP lowering efficacy estimate is limited to 
8 weeks, we cannot extrapolate our results to the longer term benefits of the treatments on 
cardiovascular morbidity and mortality. However, in this regard, the 2007 European Society of 
Hypertension (ESH)/European Society of Cardiology (ESC) guidelines are pertinent, which 
state that the size of BP reduction is more important than the class used for cardiovascular 
event reduction (Mancia et al., 2007). Thirdly, an overall of 87% patients included in the RCTs 
analysed were Caucasian, which greatly limits the extraction of conclusions for hypertensive 
patients of other races/ethnicities. Actually, blacks are known to have a less responsive renin-
angiotensin-aldosterone system (He et al., 2001) and ACE inhibitors and angiotensin receptor 
antagonists are less effective in this subpopulation (Cushman et al., 2000; Brewster et al., 2004). 
One other limitation is based on the fact that there is only one clinical trial investigating the 
antihypertensive efficacy of the lowest dose of aliskiren/HCTZ commercially available 
(150/12.5 mg), which, additionally, lacks information on outcome variability (SEM or CI) 
(Villamil et al., 2007). This fact was responsible for an unexpected higher efficacy of 
aliskiren/HCTZ 150/12.5 mg in reducing SBP and DBP, when compared with higher 
combination dosages (Table 5). Further studies are required to accurately evaluate the dose-
related antihypertensive efficacy of the commercially available aliskiren/HCTZ combinations. 
7. Conclusion 
In conclusion, aliskiren/HCTZ combinations commercially available were effective and 
generally well tolerated in clinical trials evaluating its antihypertensive effects in adults with 
mild to moderate hypertension and in hypertensive patients with obesity, providing 
clinically significant additional BP reductions and improved BP control rates in patients 
who are inadequately controlled with aliskiren or HCTZ monotherapy. The aliskiren/HCTZ 
SPCs present the convenience of a once-daily single-tablet treatment regimen, which may 
improve treatment adherence and subsequent BP control. Further studies are required to 
evaluate the relative benefits of the aliskiren/HCTZ SPCs with generically available 
alternatives. Also, long-term trials evaluating the efficacy and tolerability of this 
combination therapy would be of interest to establish the ultimate effects of treatment on the 
cardiovascular morbidity and mortality of hypertension. 
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